They don't have an agreement...yet; but RGEN's press release pasted in below suggests to me that RGEN & BMY collaborated on this study. That's a contrast to two parties waring in the courts.
“Repligen Corporation (RGEN) today noted presentation of the results of two positive Phase 3 clinical trials of CTLA4-Ig in patients with rheumatoid arthritis at the annual meeting of the American College of Rheumatology. These studies, sponsored by Bristol-Myers Squibb Company, focused on two different rheumatoid arthritis patient populations: those who do not adequately respond to treatment with methotrexate and those who do not respond to the class of biologic therapy known as tumor necrosis factor (TNF) inhibitors such as Enbrel(R), Humira(R) and Remicade(R)….”
Market Data 
Markets 
AI
